Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Oxa | 2026 | Series D | $102.6M | Oxford |
| xWatts | 2026 | Seed | $2.2M | London |
| Fresh Check | 2025 | Series Unknown | $201K | London |
| Echopoint Medical | 2025 | Series Unknown | $250K | London |
| Scripta Therapeutics | 2025 | Seed | $12.0M | Oxford |
| NoBACZ | 2025 | Series Unknown | $6.4M | Cambridge |
| Trismik | 2025 | Pre-Seed | $3.0M | Cambridge |
| Enhanc3D Genomics | 2025 | Series A | $5.4M | Cambridge |
| Xampla | 2025 | Series A | $14.0M | Cambridge |
| Paragraf | 2025 | Series C | $55.0M | Somersham |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Oxa | Series D | $102.6M | Oxford, United Kingdom |
| 2 | xWatts | Seed | $2.2M | London, United Kingdom |
| 3 | Fresh Check | Series Unknown | $201K | London, United Kingdom |
| 4 | Echopoint Medical | Series Unknown | $250K | London, United Kingdom |
| 5 | Scripta Therapeutics | Seed | $12.0M | Oxford, United Kingdom |
| 6 | NoBACZ | Series Unknown | $6.4M | Cambridge, United Kingdom |
| 7 | Trismik | Pre-Seed | $3.0M | Cambridge, United Kingdom |
| 8 | Enhanc3D Genomics | Series A | $5.4M | Cambridge, United Kingdom |
| 9 | Xampla | Series A | $14.0M | Cambridge, United Kingdom |
| 10 | Paragraf | Series C | $55.0M | Somersham, United Kingdom |
Oxa develops autonomous vehicle software and hardware solutions for industrial mobility automation.
xWatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions.
Visible warning of bacterial infection in packaging.
Echopoint Medical is a medtech company
Scripta Therapeutics operates as a bio-tech company.
NoBACZ is pioneering a novel, new precision bandaging platform for the veterinary and human market.
Trismik is an early-stage company specializing in efficient real-world evaluations, particularly for LLMs.
Enhanc3D Genomics is a functional genomics company exploring the 3D organization of DNA in health and disease.
Xampla develops natural, biodegradable materials as sustainable alternatives to traditional plastics.
Paragraf develops and manufactures graphene-based electronic devices for the sensors and diagnostics markets.
Federated data science and AI platform for privacy-preserving analytics & AI/ML
Zentraxa has specialise in the design, production and testing of complex novel peptides.
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
The next step forward in orthopaedics
Cambridge Electric Cement is a sustainable cement start-up.
Cambridge GaN Devices is a semiconductor company focused on developing GaN power devices aimed at creating greener electronics.
RoboK is a computer vision startup with a mission to make all industrial workplaces safe and high-performing with AI.
Illumion developes a lab-based real-time measurement device designed to offer detailed insights into energy storage processes.
Abselion is the biological sensor for rapid and cost-effective detection of biological substances.
Echion Technologies develops XNO anode materials designed for Li-ion batteries used in heavy-duty electric vehicles.
Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.
Barocal is a refrigeration technology company that develops solid-state cooling and heating systems for efficient cooling.
Cheesecake Energy is developing advanced thermal and compressed air energy systems to store energy.
Evoralis is an enzyme development company that specializes in the discovery and development of plastic-depolymerizing enzymes.
PhoreMost is a new-model drug discovery company based in Cambridge, UK.
Parkwalk Advisors has invested in 74 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Parkwalk Advisors's top investment sectors include Biotechnology, Health Care, Software, Manufacturing, Medical. The firm invests across 46 different industry categories.
Among tracked funding rounds, Oxa received $102.6M in a Series D round. Parkwalk Advisors's total known invested capital is $1.1B.
Parkwalk Advisors's average investment size is $12.7M across its portfolio of 74 companies.
Recent Parkwalk Advisors portfolio additions include Oxa, xWatts, Fresh Check, Echopoint Medical, Scripta Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors